CF
TARS icon

Corebridge Financial’s Tarsus Pharmaceuticals TARS Stock Holding History

Corebridge Financial’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,236
Closed -$937K – 2485
2025
Q1 		$937K Sell
18,236
-53
-0.3% -$2.62K 0.01% 1288
2024
Q4 		$1.01M Sell
18,289
-1,380
-7% -$62.7K 0.01% 1316
2024
Q3 		$647K Sell
19,669
-121
-0.6% -$3.4K ﹤0.01% 1594
2024
Q2 		$538K Buy
+19,790
New +$665K ﹤0.01% 1656

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Corebridge Financial's TARS Position: Q2 2025 in Review

Corebridge Financial sold out of Tarsus Pharmaceuticals (TARS) in Q2 2025, closing a stake of 18,236 shares — an estimated $937K sold.

Corebridge Financial first reported a position in TARS in Q2 2024 and held it in 4 quarters. The position peaked at $1.01M in Q4 2024. 205 funds tracked by Wall St. Rank hold TARS as of Q2 2025.

  • Corebridge Financial reported no remaining Tarsus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 18,236 Tarsus Pharmaceuticals shares in Q2 2025, an estimated $937K.
  • Corebridge Financial first reported a position in Tarsus Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Tarsus Pharmaceuticals position peaked at $1.01M in Q4 2024.
  • 205 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.